Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:person
|
| gptkbp:birthPlace |
gptkb:Halmstad,_Sweden
|
| gptkbp:citizenship |
gptkb:Sweden
gptkb:United_States |
| gptkbp:degree |
gptkb:PhD
MD |
| gptkbp:education |
gptkb:University_of_Lund
|
| gptkbp:employer |
gptkb:Pfizer
|
| gptkbp:field |
immunology
oncology pharmaceutical research |
| gptkbp:formerPosition |
gptkb:Boehringer_Ingelheim
gptkb:AstraZeneca gptkb:Wyeth |
| https://www.w3.org/2000/01/rdf-schema#label |
Mikael Dolsten
|
| gptkbp:knownFor |
COVID-19 vaccine development at Pfizer
leadership in pharmaceutical R&D |
| gptkbp:memberOf |
gptkb:New_York_Academy_of_Sciences
gptkb:American_Association_of_Immunologists |
| gptkbp:nationality |
Swedish
|
| gptkbp:occupation |
gptkb:business_executive
gptkb:physician gptkb:scientist |
| gptkbp:position |
Chief Scientific Officer
President, Worldwide Research, Development and Medical at Pfizer |
| gptkbp:bfsParent |
gptkb:Pfizer_Inc.
gptkb:Pfizer_scientists |
| gptkbp:bfsLayer |
6
|